With a strong focus on deep thinking and deep learning, we provide premier scientific consulting and technology services to some of the world's top biotech, pharmaceutical, chemical, and cosmeceutical enterprises. Our exclusive technology enables a renaissance of small-molecule drug discovery, paving the way for custom-tailored medicines of the future. We have pioneered the development of groundbreaking algorithms such as CATS (Chemically Advanced Template Search) and DOGS (Design Of Genuine Structures), while also introducing terms like scaffold-hopping and frequent-hitters in the field of drug discovery.

Specializing in low-data molecular discovery supported by collaborative artificial intelligence, our industry-proven virtual screening methods, like CopyCATS™ and ShapeCATS™, facilitate the rapid discovery of new chemical entities with desired properties and target activities. Additionally, our software, POOMA™ (PrOjection Of Molecular Attributes), generates fitness landscapes for compound library design and enables rapid data clustering for diversity analysis. With our Collection Of Bioactive Reference Analogs (COBRA™) and unique target prediction technique TIGER™ (Target Inference GEneRator), we excel in deorphaning drugs, bioactive natural products, and phenotypic screening hits for compound library design, target-oriented hit-to-lead expansion, off-target analysis, and drug re-purposing.

At inSili. com, we also offer innovative molecular design and virtual screening solutions to automate drug discovery, enhancing chemical and pharmaceutical R&D. With our expertise, we can create new chemical entities on demand, featuring multi-target activity profiles or designer selectivity.

Additionally, we develop artificial intelligence systems that enable the discovery of bioactive chemical entities with desired properties. Stay at the forefront of pharmaceutical innovation with inSili. com